Intrinsiqs

Is Crinetics Pharmaceuticals, Inc. overvalued?

Crinetics Pharmaceuticals, Inc. (CRNX) — key valuation metrics and fundamentals.

No verdict
Price
$84.44
Fair value
Current P/E
Normal P/E
Market cap
$8.95B
Dividend yield
0.0%
Return on equity
-44.2%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CRNX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.